中程度から重度の尋常性乾癬患者を対象としたORKA-001の用量設定試験 (EVERLAST-B)
中等症から重症の尋常性乾癬を有する参加者を対象とした、ORKA-001の多施設共同、無作為化、二重盲検、プラセボ対照、用量範囲設定試験
This is a multicenter, randomized, double-blinded, placebo-controlled, dose-range finding study to evaluate the efficacy and safety of ORKA-001 in adult participants with moderate-to-severe plaque psoriasis.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
This is a multicenter, randomized, double-blinded, placebo-controlled, dose ranging study designed to identify the optimal induction dosing regimen of ORKA-001 in approximately 160 adult participants with moderate-to-severe plaque psoriasis.
The study will evaluate the efficacy and safety of 3 induction dosing regimens of ORKA-001 compared to placebo and will include 3 maintenance regimens.
The study will consist of 4 periods:
- Screening Period of up to 6 weeks
- Induction Period of up to 28 weeks (Day 1 [Baseline] to Week 28)
- Maintenance Period of up to approximately 72 weeks (Week 28 to Week 100)
- Post-treatment Follow-up Period: Participants will have the option to enter the open-label extension (OLE) study. Participants who opt out of the OLE study and/or withdraw from the study must be followed for 48 weeks after the End of Treatment (EOT)/Early Termination (ET) visit.
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- フェーズ2
連絡先と場所
研究場所
-
-
Arizona
-
Phoenix、Arizona、アメリカ、85032
- Oruka Therapeutics Investigative Site
-
-
Arkansas
-
North Little Rock、Arkansas、アメリカ、72117
- Oruka Therapeutics Investigative Site
-
-
California
-
Los Angeles、California、アメリカ、90045
- Oruka Therapeutics Investigative Site
-
Los Angeles、California、アメリカ、90024
- Oruka Therapeutics Investigative Site
-
San Diego、California、アメリカ、92123
- Oruka Therapeutics Investigative Site
-
-
Florida
-
Miami、Florida、アメリカ、33126
- Oruka Therapeutics Investigative Site
-
-
Illinois
-
Rolling Meadows、Illinois、アメリカ、60008
- Oruka Therapeutics Investigative Site
-
-
Indiana
-
Plainfield、Indiana、アメリカ、46168
- Oruka Therapeutics Investigative Site
-
-
Maryland
-
Rockville、Maryland、アメリカ、20850
- Oruka Therapeutics Investigative Site
-
-
New York
-
Kew Gardens、New York、アメリカ、11415
- Oruka Therapeutics Investigative Site
-
-
North Carolina
-
Chapel Hill、North Carolina、アメリカ、27516
- Oruka Therapeutics Investigative Site
-
-
Ohio
-
Cleveland、Ohio、アメリカ、44106
- Oruka Therapeutics Investigative Site
-
Mason、Ohio、アメリカ、45040
- Oruka Therapeutics Investigative Site
-
-
Oregon
-
Portland、Oregon、アメリカ、97201
- Oruka Therapeutics Investigative Site
-
Portland、Oregon、アメリカ、97210
- Oruka Therapeutics Investigative Site
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、アメリカ、19104
- Oruka Therapeutics Investigative Site
-
-
Texas
-
Frisco、Texas、アメリカ、75033
- Oruka Therapeutics Investigative Site
-
Houston、Texas、アメリカ、77004
- Oruka Therapeutics Investigative Site
-
Webster、Texas、アメリカ、77598
- Oruka Therapeutics Investigative Site
-
-
Virginia
-
Norfolk、Virginia、アメリカ、23502
- Oruka Therapeutics Investigative Site
-
-
-
-
British Columbia
-
Surrey、British Columbia、カナダ、V3R 6A7
- Oruka Therapeutics Investigative Site
-
Surrey、British Columbia、カナダ、V3V 0C6
- Oruka Therapeutics Investigative Site
-
-
New Brunswick
-
Fredericton、New Brunswick、カナダ、E3B 1G9
- Oruka Therapeutics Investigative Site
-
-
Ontario
-
Ajax、Ontario、カナダ、L1S 7K8
- Oruka Therapeutics Investigative Site
-
Markham、Ontario、カナダ、L3P 1X3
- Oruka Therapeutics Investigative Site
-
Peterborough、Ontario、カナダ、K9J 5K2
- Oruka Therapeutics Investigative Site
-
-
Quebec
-
Montreal、Quebec、カナダ、HZX 2V1
- Oruka Therapeutics Investigative Site
-
Québec、Quebec、カナダ、G1V 4X7
- Oruka Therapeutics Investigative Site
-
-
-
-
Barcelona
-
Badalona、Barcelona、スペイン、08916
- Oruka Therapeutics Investigative Site
-
Barcelona、Barcelona、スペイン、08041
- Oruka Therapeutics Investigative Site
-
-
Madrid
-
Madrid、Madrid、スペイン、28002
- Oruka Therapeutics Investigative Site
-
Madrid、Madrid、スペイン、28046
- Oruka Therapeutics Investigative Site
-
-
-
-
Baden-Wuerrtemberg
-
Heidelberg、Baden-Wuerrtemberg、ドイツ、69120
- Oruka Therapeutics Investigative Site
-
-
Hesse
-
Frankfurt am Main、Hesse、ドイツ、60590
- Oruka Therapeutics Investigative Site
-
-
Lower Saxony
-
Bad Bentheim、Lower Saxony、ドイツ、48455
- Oruka Therapeutics Investigative Site
-
-
Schleswig-Holstein
-
Kiel、Schleswig-Holstein、ドイツ、24105
- Oruka Therapeutics Investigative Site
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Participants ≥ 18 years of age
-
Have a diagnosis of plaque psoriasis for > 6 months
-
Have moderate-to-severe chronic plaque psoriasis defined as:
- BSA ≥ 10%, and
- PASI ≥ 12, and
- IGA score of ≥ 3 on a 5-point scale
-
Candidate for systemic therapy or phototherapy
-
Women of childbearing potential must have a negative pregnancy test.
Exclusion Criteria:
- Nonplaque forms of psoriasis (including guttate, erythrodermic, or pustular) or drug-induced psoriasis
- Significant history or clinical manifestation of any metabolic, other dermatological, hepatic, renal, hematologic, pulmonary, cardiovascular, gastrointestinal, neurologic, respiratory, endocrine, or psychiatric disorder, or any infectious disease
- History of malignancy, except for non-melanoma skin cancer or cancer curatively treated ≥ 5 years, without evidence of recurrence
- A known hypersensitivity to any components of the ORKA-001 drug product
- Women who are breastfeeding or plan to breastfeed during the study
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:ダブル
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:(Induction Period - Arm 1) ORKA-001
Participants will receive 37.5 mg ORKA-001 per protocol Induction regimen. |
ORKA-001 administered by subcutaneous (SC) injection |
|
実験的:(Induction Period - Arm 2) ORKA-001
Participants will receive 300 mg ORKA-001 per protocol Induction regimen. |
ORKA-001 administered by subcutaneous (SC) injection |
|
実験的:(Induction Period - Arm 3) ORKA-001
Participants will receive 600 mg ORKA-001 per protocol Induction regimen. |
ORKA-001 administered by subcutaneous (SC) injection |
|
プラセボコンパレーター:(Induction Period - Arm 4) Placebo
Participants will receive Placebo per protocol Induction regimen. |
Placebo administered by subcutaneous (SC) injection |
|
実験的:(Maintenance Period - Arm 1) ORKA-001
Participants will receive 300 mg ORKA-001 per protocol Maintenance regimen, based on protocol defined response. |
ORKA-001 administered by subcutaneous (SC) injection |
|
実験的:(Maintenance Period - Arm 2) ORKA-001
Participants will receive 600 mg ORKA-001 per protocol Maintenance regimen, based on protocol defined response. |
ORKA-001 administered by subcutaneous (SC) injection |
|
プラセボコンパレーター:(Maintenance Period - Arm 3) Placebo
Participants will receive Placebo per protocol Maintenance regimen, based on protocol defined response. |
Placebo administered by subcutaneous (SC) injection |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Proportion of Participants Achieving 100% Reduction in PASI Score at Week 16
時間枠:Week 16
|
The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease). |
Week 16
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Proportion of Participants Who Achieve an IGA = 0 (Clear) at Week 16
時間枠:Week 16
|
The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4). |
Week 16
|
|
Proportion of Participants Achieving 90% Reduction in PASI Score at Week 16
時間枠:Week 16
|
Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease). |
Week 16
|
|
Proportion of Participants Who Achieve an IGA = 0 (Clear) or 1 (Almost Clear) at Week 16
時間枠:Week 16
|
The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4). |
Week 16
|
|
Proportion of Participants Maintaining 100% Reduction in PASI Score at Week 100
時間枠:Week 100
|
The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease). |
Week 100
|
|
Proportion of Participants Maintaining an IGA = 0 (Clear) at Week 100
時間枠:Week 100
|
The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4). |
Week 100
|
|
Proportion of Participants Maintaining 90% Reduction in PASI Score at Week 100
時間枠:Week 100
|
The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease). |
Week 100
|
|
Proportion of Participants Maintaining an IGA = 0 (Clear) or 1 (Almost Clear) at Week 100
時間枠:Week 100
|
The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4). |
Week 100
|
|
Proportion of Participants Maintaining 75% Reduction in PASI Score at Week 100
時間枠:Week 100
|
The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease). |
Week 100
|
|
Incidence of Treatment-emergent Adverse Events (TEAEs) and TEAEs of Special Interest (TEAESIs)
時間枠:Day 1 through Week 100
|
Incidence of treatment adverse events, treatment adverse events of special interest, and clinically significant changes from baseline in vital signs, clinical laboratory parameters and electrocardiograms |
Day 1 through Week 100
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (実際)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。